ArticleDiscover oncology2026
Global regional and national burden of nonmelanoma skin cancer from 1990 to 2021 based on the global burden of disease 2021 study.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Temporal Trends of Melanoma and Non-Melanoma Skin Cancer Mortality Rates in Hungary Between 1980 and 2020.Cancers · 2026Article
- Automated Skin Lesion and Cancer Detection Using Computer Vision: A Comprehensive Review.Bioengineering (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-melanoma skin cancer (NMSC) is the most common cancer type globally, with a significantly higher incidence than other types of skin cancer. However, detailed analyses of the global burden of disease and changing trends in NMSC remain scarce.
methodsWe extracted data from the Global Burden of Disease (GBD) 2021 to assess the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) associated with NMSC at the global, regional, and country levels. Linear regression models were used to analyze temporal trends in the global burden of disease from 1990 to 2021. Additionally, frontier analyses were conducted to determine the minimum achievable incidence, prevalence, morbidity, mortality, and DALYs.
resultsIn 2021, NMSC caused 56,913 deaths and resulted in a reduction of 1,212,872 DALYs globally. The age-standardized prevalence of NMSC increased from 18.42 (95% UI, 15.26-22.12) cases per 100,000 people in 1990 to 32.51 (95% UI, 28.22-37.54) cases per 100,000 people in 2021. The burden of disease increases with age. The prevalence is consistently higher in men than in women. Prevalence rates were highest in high SDI regions such as the United States, Northern Europe, and North America. Conversely, mortality rates were highest in low SDI regions, including Latin America and the Caribbean. Furthermore, countries with higher Human Development Index (HDI) scores exhibited lower age-standardized mortality rates and DALYs for NMSC.
conclusionThe global burden of NMSC is increasing. Effective prevention strategies and public health policies are urgently needed to reduce this burden and improve overall health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.